A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Exclusion criteria

• . History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE v5.0 ≥ Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.
• . Congenital long QT syndrome.
• . Corrected QT interval (QTcF) prolongation to \>470 msec (females) or \>450 msec (males) based on average of the screening triplicate 12-lead ECG.
• . History of QT prolongation associated with other medications that required discontinuation of that medication.
• . History of symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), left ventricular systolic dysfunction, or decrease in ejection fraction.
• . History of myocardial infarction, unstable angina, vascular stenting, angioplasty, or other cardiac surgery within 6 months prior to first dose of study treatment.
• . Uncontrolled or poorly controlled hypertension (\>180 mmHg systolic or \>130 mmHg diastolic) despite medical treatment.
• . History of non-infectious ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.